• View the Talks
• 64 min
  1. Current trends in antiviral drug development

  • Prof. Dr. Erik De Clercq
• 76 min
  2. Antivirals versus vaccines

  • Prof. Albert D.M.E. Osterhaus
• 58 min
  3. Prospects of anti-HIV therapy and prophylaxis

  • Prof. Dr. Erik De Clercq
• 38 min
  4. Systemic RNA interference (RNAi) therapeutics for the treatment of HIV-1

  • Prof. John Rossi
• 9 min
  5. The path towards a cure for chronic hepatitis B

  • Prof. Fabien Zoulim
• 70 min
  6. Influenza antivirals: update

  • Prof. Frederick G. Hayden
• 35 min
  7. Herpes simplex virus and varicella-zoster virus helicase-primase inhibitors

  • Dr. Hugh J. Field
• 45 min
  8. Nucleoside phosphonates as inhibitors of HIV

  • Dr. Tomas Cihlar
• 59 min
  9. HIV-1 integrase inhibitors

  • Prof. Martin Markowitz
• 52 min
  10. Cellular cofactors of HIV integrase: from target identification to discovery of ledgins

  • Prof. Zeger Debyser
• 32 min
  11. HIV entry inhibitors

  • Prof. José Esté
• 39 min
  12. Antiviral therapy of orthopoxvirus infection

  • Prof. Earl R. Kern
  • Prof. Mark N. Prichard
• 25 min
  13. Herpes simplex virus antiviral chemotherapy

  • Dr. Hugh J. Field
• 30 min
  14. Cyclophilin inhibitors for HCV

  • Prof. Robert Flisiak
• Archived Lectures *These may not cover the latest advances in the field
• 50 min
  15. Towards the development of potent therapy against the hepatitis C virus

  • Prof. Johan Neyts
• 62 min
  16. Antiviral therapy of chronic hepatitis B virus infections: is resistance still a challenge?

  • Prof. Fabien Zoulim

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Talk outline
3. HIV integrase
4. Integrase function and proviral DNA integration
5. Strand transfer inhibitors of HIV-1 integrase
6. Clinically relevant HIV-1 integrase inhibitors
7. Raltegravir (MK-0518, Isentress)
8. Pivotal trials of raltegravir
9. Study 004 proof of concept
10. Protocol 004 phase Iib
11. Study 004: week 96 virology
12. Results: study 004
13. BENCHMRK 1 and 2, phase III
14. BENCHMRK 1 and 2: baseline characteristics (1)
15. BENCHMRK 1 and 2: baseline characteristics (2)
16. BENCHMRK 1 and 2: virologic response
17. BENCHMRK: subgroup analyses
18. BENCHMRK: response with additional ARVs
19. BENCHMRK: 96 week results
20. BENCHMRK: conclusions
21. Lessons from BENCHMRK: the TRIO study
22. STARTMRK study
23. STARTMRK: week 48 virology
24. STARTMRK: subgroup analyses
25. STARTMRK: week 48 CD4+T cell count response
26. STARTMRK: adverse events
27. STARTMRK: wk 96 lipid profiles
28. STARTMRK: conclusions
29. SWITCHMRK
30. SWITCHMRK1: lipids at week 12
31. SWITCHMRK: week 24 virology
32. SWITCHMRK: week 24 virology subset analysis
33. SWITCHMRK: conclusions
34. SPIRAL
35. SPIRAL: results - virology
36. SPIRAL: results - lipid profiles
37. SPIRAL: conclusions
38. Raltegravir development: future directions
39. Elvitegravir (GS-9137)
40. Elvitegravir development
41. Study 0101 monotherapy proof of concept trial
42. Study 0105
43. Study 0105: baseline characteristics
44. Study 0105: DSMB review at week 8
45. Study 0105: change in HIV-1 RNA levels
46. Study 0105: subset analyses - virology
47. Study 0105: conclusions
48. QUAD: ELV, PK enhancer and TDF/FTC
49. Study 236-0104: phase II QUAD
50. Study 236-0104: patient disposition
51. Study 236-0104: results week 48
52. Study 236-0104: clinical adverse events
53. Study 236-0104: effects of cobicistat on eGFR
54. Study 236-0104: conclusions
55. S/GSK-572
56. S/GSK 572: 10-day mono therapy
57. SPRING 1: study design
58. SPRING 1: antiviral activity
59. SPRING 1: conclusions
60. Resistance to InSTIs: general features
61. BENCHMRK: resistance analyses
62. STARTMRK: resistance results
63. Clonal analyses of viruses
64. Resistance to elvitegravir
65. RAL and EVG are cross resistant
66. In vitro passage results
67. 572 is non cross resistant to RAL and EVG
68. Viking cohort 1: study design
69. VIKING: day 11 results
70. VIKING: virologic response and susceptibility
71. VIKING: conclusions
72. Talk summary and conclusions

Topics Covered

• HIV integrase and the viral life cycle
• General features of integrase inhibitors
• Clinical profiles of clinically relevant strand transfer integrase inhibitors
• Raltegravir, elvitegravir and s/GSK 572
• Resistance and cross resistance to integrase inhibitors

Links

Series:

• Antivirals

Categories:

• Biochemistry
• Clinical Practice
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases

Talk Citation

Publication History

• Published on August 30, 2011

Financial Disclosures

• Prof. Martin Markowitz has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.